
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Frank A. Oski, Walter W. Tunnessen, and Catherine Caldwell Brown are remembered by a colleague for their inestimable contribution to this publication.






